News
The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback